RATIONALE: The underlying etiology in inflammatory bowel diseases such as Ulcerative Colitis is not yet fully understood. Studies suggest a relation between higher intestinal permeability and aberrant changes of the epithelium. Dysbiosis of the intestinal microbiota might be the cause. Probiotics may restore the balance of the intestinal microbiota. In theory this could improve intestinal permeability and therefore reduce disease activity and maintain remission in patients with Ulcerative Colitis. OBJECTIVE: To investigate whether a specifically designed multispecies probiotic mixture (ecologic 825®), as adjuvant therapy, can contribute to an improvement of intestinal permeability, microbiota composition, disease activity and inflammatory markers in ulcerative colitis. STUDY DESIGN: 12-wk placebo-controlled randomized double-blind intervention with 2 parallel arms. STUDY POPULATION: Adults diagnosed with left sided Ulcerative Colitis or Pancolitis in remission or mild stage of the disease. For inclusion of the patients the Patient Simple Clinical Colitis Activity Index (P-SCCAI) will be used. INTERVENTION: Patients will receive either two daily dosages of 3 g of Ecologic® 825 or two daily doses of 3 g of the placebo, containing only the carrier material (both produced by Winclove Probiotics). MAIN STUDY PARAMETERS/ENDPOINTS: Main study parameter is intestinal permeability measured by several techniques: the lactulose/mannitol absorption test (L/M test), LPS levels in blood serum and faecal zonulin. Secondary, inflammation will be measured from faecal calprotectin and blood c-reactive protein (CRP) levels. Furthermore samples will be stored to measure cytokine concentrations in serum and to analyse the microbial composition of the faecal samples using the HITchip. For the disease related quality of life the irritable bowel disease questionnaire (IBD-Q) and SF-36 will be used. All parameters will be measured at three time points; t=0, t=6 and t=12 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Enrollment
40
Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
Placebo
Gelderse Vallei Hospital
Ede, Netherlands
Intestinal permeability measured by the Lactulose Mannitol test (L/M test)
Measured by the Lactulose Mannitol ratio in urine (L/M test)
Time frame: 12 weeks
blood CRP levels
inflammatory marker
Time frame: 6 and 12 weeks
fecal calprotectin levels
marker of intestinal inflammation
Time frame: 6 and 12 weeks
Quality of life (measured by IBD-Q and SF36)
Disease related quality of life will be measured by IBD-Q and SF36
Time frame: 6 and 12 weeks
Intestinal permeability measured by the Lactulose Mannitol test (L/M test)
Measured by the Lactulose Mannitol ratio in urine (L/M test)
Time frame: 6 weeks
Lipopolysaccharides levels in blood
A marker for intestinal permeability and inflammation
Time frame: 6 and 12 weeks
Intestinal permeability measured by faecal zonulin levels
Measured by faecal zonulin levels
Time frame: 6 and 12 weeks
microbiota composition
measured by human intestinal tract (HIT-chip) microarray
Time frame: 6 and 12 weeks
interferon gamma levels
measured in plasma samples
Time frame: 6 and 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.